Geron to Announce First Quarter 2021 Financial Results on May 10, 2021

Rhea-AI Summary

Geron Corporation (Nasdaq: GERN) will release its first quarter 2021 financial results on May 10, 2021, after market close. A conference call will follow at 4:30 p.m. ET to discuss results and recent developments. Investors can access the press release and the live webcast on the company's website. Geron is advancing a first-in-class telomerase inhibitor, imetelstat, targeting hematologic malignancies and is currently conducting two Phase 3 trials: IMerge and IMpactMF. For further information, visit www.geron.com.

Positive

• Conducting two Phase 3 clinical trials (IMerge and IMpactMF) for imetelstat in hematologic malignancies.

Negative

• None.

Geron Corporation (Nasdaq: GERN) today announced that it will release its first quarter 2021 financial results after the market closes on Monday, May 10, 2021 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.

A live, listen-only webcast will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the conference call live via telephone by pre-registering online using the following link, http://www.directeventreg.com/registration/event/2456438. Upon registration, a phone number, Direct Event Passcode and unique Registrant ID will be sent via email. This information will be needed in order to enter the conference call. Participants are advised to pre-register at least 10 minutes prior to joining the call.

About Geron

Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis. For more information about Geron, visit www.geron.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210503005729/en/

FAQ

When will Geron Corporation release its Q1 2021 financial results?

Geron Corporation will release its Q1 2021 financial results after market close on May 10, 2021.

What time is Geron's conference call to discuss Q1 2021 results?

The conference call to discuss the Q1 2021 results will be held at 4:30 p.m. ET on May 10, 2021.

Where can I find Geron's Q1 2021 earnings report?

Geron's Q1 2021 earnings report will be available on their website at www.geron.com/investors.

What clinical trials is Geron currently conducting?

Geron is currently conducting two Phase 3 clinical trials: IMerge in lower risk myelodysplastic syndromes and IMpactMF in refractory myelofibrosis.